About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Breaking A Very Long Silence | Main | Patent Profile: MorphoSys Announces Issuance of Human Combinatorial Antibody Library (HuCAL) Patent »

October 02, 2007

Bristol-Myers Squibb Acquires Adnexus Therapeutics

    By Sherri Oslick --

Bristolmyers_squibb_1 Last week, Bristol-Myers Squibb Co. of Princeton, NJ announced that it would acquire biotechnology company Adnexus Therapeutics Inc. of Waltham, MA for $430 million in cash (with an additional $75 million to be paid provided Adnexus meets certain regulatory milestones).  Adnexus is a privately held company developing a proprietary class of protein-based targeted biologics called Adnectins.

Pic_global_logo Following acquisition, Adnexus will be a subsidiary of BMS.  Adnexus' portfolio includes oncology biologic Angiocept, an antagonist of the VEGFR-2 pathway currently in Phase I trials.  Adnexus' patent portfolio includes over 100 issued and pending patent properties relating to Adnectins and PROfusion, Adnexus' proprietary protein engineering system.

For more information, please see:

Posted at 08:53 PM in Licensing |

Comments

The comments to this entry are closed.

May 2025

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Categories

Archives

More...